Medication info
Ibandren 150 mg (Ibandronic Acid Sodium Hydrate)

Ibandren 150 mg (Ibandronic Acid Sodium Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Ibandronate Sodium Monohydrate›168.75mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
[For domestic] White to nearly white, oblong film-coated tablet [For export] Pink, oblong film-coated tablet
Packaging
1 tablet/PTP
Approval status
Active

MFDS item code 201205833 · Notified 2012.06.22 · Insurance code 698502260

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who takes it
Adults · Children
Adult dose
Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (other than water), or other oral medications or dietary supplements (including calcium): - This medicine must be swallowed with a sufficient amount of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine; take it with plain water. - To prevent esophageal ulcers, do not chew or suck the tablet. If a patient forgets to take the medicine on the regularly scheduled dosing day - If 8 days or more remain until the next regularly scheduled dosing day, take 1 tablet the morning after realizing that a dose was missed, and thereafter take 1 tablet each month on the previously scheduled dosing day. - If 7 days or fewer remain until the next regularly scheduled dosing day, take 1 tablet on the next regularly scheduled dosing day, and thereafter continue to take 1 tablet each month on the previously scheduled dosing day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment with a creatinine clearance of 30mL/min or more. Use of this medicine is not recommended in patients with a creatinine clearance of less than 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.
Child dose
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that occurs in postmenopausal women. Osteoporosis is a condition in which bones become weak and the risk of fractures increases, particularly occurring in women after menopause. This medication helps increase bone strength and maintain bone density to reduce the risk of fractures. Therefore, it is effective for the prevention and treatment of fractures caused by postmenopausal osteoporosis.

How to take

Adult dose

Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (other than water), or other oral medications or dietary supplements (including calcium): - This medicine must be swallowed with a sufficient amount of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine; take it with plain water. - To prevent esophageal ulcers, do not chew or suck the tablet. If a patient forgets to take the medicine on the regularly scheduled dosing day - If 8 days or more remain until the next regularly scheduled dosing day, take 1 tablet the morning after realizing that a dose was missed, and thereafter take 1 tablet each month on the previously scheduled dosing day. - If 7 days or fewer remain until the next regularly scheduled dosing day, take 1 tablet on the next regularly scheduled dosing day, and thereafter continue to take 1 tablet each month on the previously scheduled dosing day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment with a creatinine clearance of 30mL/min or more. Use of this medicine is not recommended in patients with a creatinine clearance of less than 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.

Child dose

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication should not be administered to certain patients. Firstly, patients who are allergic to this medication or any of its components should not use it. Additionally, untreated hypocalcemia can make taking this medication risky. Patients who cannot maintain an upright position for at least 60 minutes after taking the medication should not use it. Patients with esophageal conditions that prevent swallowing, such as esophageal strictures or achalasia, should also avoid this medication. This medication contains lactose, so patients with lactose intolerance, galactose intolerance, or certain genetic metabolic disorders should refrain from taking it. Caution is advised when administering this medication to patients with severe renal failure; careful monitoring by a doctor is required in this case. Common side effects when taking this medication may include dyspepsia, nausea, abdominal pain, diarrhea, headaches, muscle pain, joint pain, rashes, or others. Some patients may experience flu-like symptoms, such as joint pain, muscle pain, fever, chills, and fatigue, temporarily. Furthermore, gastrointestinal issues, such as esophagitis, esophageal ulcers, or esophageal strictures, may occur; therefore, if symptoms like difficulty swallowing, pain while swallowing, chest pain, or heartburn appear, immediate cessation of the medication and a consultation with a doctor is necessary. This medication may irritate the gastric mucosa, so patients with upper gastrointestinal disorders such as gastritis or duodenitis should use it with caution. Bisphosphonate medications can be associated with osteonecrosis of the jaw; thus, it is recommended to have a dental examination before any dental treatments and to avoid excessive dental treatments during the course of treatment. There have also been rare reports of inflammatory conditions of the eye, severe allergic reactions, skin conditions, and atypical fractures of the femur; thus, if any of these symptoms occur, immediate consultation with medical professionals is necessary. This medication may hinder the absorption of calcium, milk, antacids, etc.; therefore, do not take food or other medications for at least 1 hour after taking it. The safety of this medication during pregnancy or breastfeeding has not been established; it is advisable not to use it if pregnant or breastfeeding. No special dosage adjustment is required for the elderly, but safety and efficacy have not been confirmed for children under 18 years of age. In case of overdose, gastrointestinal disturbances or hypocalcemia may occur, so it is important to avoid exceeding the recommended dose. Finally, this medication should be stored out of reach of children, and unused medications should be disposed of properly to prevent environmental contamination.

Side effects

Dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, esophageal stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial edema, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external ear, anaphylactic reaction, shock, worsening of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral and subtrochanteric fracture, atypical fracture of the iliac bone, paraesthesia of the eye, weakness, pruritus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Also, avoid storing it in extremely hot or cold places, and it is advisable to keep it at room temperature between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

[For domestic] White to nearly white, oblong film-coated tablet [For export] Pink, oblong film-coated tablet

Package unit

1 tablet/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.